Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/228117
Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Integrase strand inhibitor (INSTI)-based antiretroviral regimens are the preferred choices for treating people with human immunodeficiency virus (PWH). The once-daily single-tablet combination of INSTI bictegravir, co-formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), has shown effectiveness and good tolerability in randomized clinical trials, both in treatment-na & iuml;ve (TN) and virologically suppressed patients switched to this regimen. Real-world evidence represents clinical practice and may fill data gaps left by piv otal studies. Based on literature search for real-world studies in Spain within five years, and using clinical trial data as a contextual framework, this narrative review synthesizes observational experience with BIC/FTC/TAF, focusing on the interplay between comorbidities, advanced age, and treatment outcomes from underrepre sented subgroups in clinical trials. This fixed-dose combination proved effective and well-tolerated for TN and treatment-experienced PWH, with low virological failure even in difficult-to-treat patients. Low rates of treatment discontinuations due to adverse events or drug-drug interactions aligned with clinical trial findings.
Matèries
Matèries (anglès)
Citació
Citació
AMADOR PROUS, Concha, et al. Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years. Enfermedades Infecciosas y Microbiología Clínica. 2025. Vol. 44, num. 2. ISSN 0213-005X. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/228117